Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merck & Company (DE:6MK)
XETRA:6MK
Holding DE:6MK?
Track your performance easily
6MK Stock Chart & Stats
Day’s Range― - ―
52-Week Range€89.60 - €125.60
Previous CloseN/A
Volume75.00
Average Volume (3M)1.19K
Market Cap
$246.95B
Enterprise Value€312.11B
Total Cash (Recent Filing)$14.34B
Total Debt (Recent Filing)$24.27B
Price to Earnings (P/E)22.1
Beta0.15
Next Earnings
Feb 04, 2025EPS Estimate
1.7Last Dividend Ex-Date
Dec 16, 2024Dividend Yield3.1%
Share Statistics
EPS (TTM)4.40
Shares Outstanding2,529,635,700
10 Day Avg. Volume946
30 Day Avg. Volume1,193
Standard Deviation0.06
R-Squared0.04
Alpha0.00733
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.03
Price to Cash Flow (P/CF)6.90
P/FCF Ratio7.50
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue4.94
Enterprise Value/Gross Profit7.10
Enterprise Value/Ebitda16.51
Forecast
1Y Price Target
€120.33Price Target Upside25.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Merck & Company News
Bulls Say, Bears Say
Bulls Say
Cardiometabolic StrategyMRK has entered into a global license agreement with Hansoh Pharma for HS-10535, a preclinical oral small molecule GLP-1 receptor agonist for diabesity, adding to MRK's cardiometabolic portfolio and providing a potential asset that could enter the future $150bn diabesity market.
Oncology PipelineMRK increased its long-term oncology sales target to over $25 billion, reflecting confidence in its oncology pipeline and new product developments.
Product LaunchesImpressive launches with clesrovimab (RSV) and Capvaxive (pneumococcal), as well as building revenue with Winrevair (PAH) through European launch and expansion in the US could provide significant support for the stock.
Bears Say
Pipeline And Product ChallengesMRK announced it is discontinuing pipeline programs for vibostolimab and favezelimab, which are next-gen immuno-oncology assets the company was exploring in combination with Keytruda.
Product Development And CompetitionObesity development strategy shows Merck is significantly delayed relative to other competitors.
Revenue And Market CompetitionThe price target for MRK has been lowered from $136 to $119 due to increased risk for Keytruda revenue following loss-of-exclusivity and Medicare IRA price caps.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.04% Insiders
21.76% Mutual Funds
0.67% Other Institutional Investors
56.78% Public Companies and Individual Investors
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €89.60 and its highest was €125.60 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $246.95B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Feb 04, 2025 which is in 16 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Oct 31, 2024. The company reported €1.524 earnings per share for the quarter, beating the consensus estimate of €1.441 by €0.083.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of €3.022 which represents an annual dividend yield of 3.1%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 1.7.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,529,635,700 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of €1.524 in its last earnings report, beating expectations of €1.441. Following the earnings report the stock price went down -1.569%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in DE:6MK
---
Merck & Company Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€120.33 (25.22% Upside)
€120.33 (25.22% Upside)
Blogger Sentiment
Bullish
DE:6MK Sentiment 86%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.84%
12-Months-Change
Fundamentals
Return on Equity
28.33%
Trailing 12-Months
Asset Growth
10.12%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
---
6MK Company Deck
---
6MK Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several strong performance areas, such as revenue growth driven by KEYTRUDA and animal health, and a robust pipeline expansion. However, challenges in China and the decline in GARDASIL sales, particularly in China, were notable lowlights. Overall, the sentiment leans towards positive due to strong growth drivers and future potential.Read More>---
6MK Sales Breakdown
89.13% Pharmaceutical
9.36% Animal Health
1.51% Other
---
6MK Stock 12 Month Forecast
Average Price Target
€120.33
▲(25.22% Upside)
Technical Analysis
Merck & Company
―
Pfizer
―
Johnson & Johnson
―
AbbVie
―
Bristol-Myers Squibb
―
GlaxoSmithKline
―
Novartis
―
Best Analysts Covering 6MK
1 Year
1 Year Success Rate
39/53 ratings generated profit
1 Year Average Return
+12.86%
reiterated a buy rating 12 months ago
Copying Mara Goldstein's trades and holding each position for 1 Year would result in 73.58% of your transactions generating a profit, with an average return of +12.86% per trade.
---